

## Evaluation Report for Category B, Subcategory 3.2 Application

**Application Number:** 2020-5252  
**Application:** Change to End-Use Product Label – Application Timing  
**Product:** Edge MicroActiv Herbicide  
**Registration Number:** 20980  
**Active ingredient (a.i.):** Ethalfluralin  
**PMRA Document Number:** 3325829

### Purpose of Application

The purpose of this application was to amend the label of Edge MicroActiv Herbicide to add a spring application timing for direct seeding systems for lentils to control and suppress labelled weeds.

### Chemistry Assessment

A chemistry assessment was not required for this application.

### Health Assessments

A toxicological assessment was not required for this application.

The addition of a spring timing of application for lentils on the label of Edge MicroActiv Herbicide represents an expansion of the use pattern for the active ingredient ethalfluralin. Updated non-cancer and cancer quantitative risk assessments for mixers, loaders and applicators were not required since the most recent risk assessments on file were conducted with input parameters applicable to the exposure scenario. Postapplication worker exposure and bystander exposure are expected to be negligible due to the application timing and method (i.e., a preplant incorporated or direct-seeding application of a granular product). Therefore, no health risks of concern were identified and the use can be supported from an occupational exposure perspective provided that workers wear the appropriate personal protective equipment and follow all label directions.

No new residue data for ethalfluralin were submitted to support the addition of the new spring preplant application to fields of lentils. Previously reviewed residue data from field trials conducted in/on dry peas, dry beans and dry lentils were re-assessed in the framework of this application and were deemed acceptable. The currently established MRL of 0.05 ppm for residues of ethalfluralin in/on dry lentils is adequate to cover the new application timing and no health risks of concern were identified for acute, chronic or cancer dietary exposure (food and drinking water) to any segment of the population, including infants, children, adults and seniors.

## **Environmental Assessment**

No additional environmental risk is expected from the spring application of Edge MicroActiv Herbicide to lentils. The label includes all the required environmental precautions and directions for use statements, which adequately mitigates risks to the environment.

## **Value Assessment**

The amendment to the registration of Edge MicroActiv Herbicide to include a spring application timing on lentils in direct seeding systems provides growers more flexibility to employ this product for control of volunteer cereals, annual grasses, and broadleaf weeds in this crop.

Value information submitted for review consisted of a scientific rationale and data from replicated field trials. This information demonstrated that lentils exhibited an adequate margin of tolerance to a spring application of Edge MicroActiv Herbicide in direct seeding systems when used as per the label instructions.

## **Conclusion**

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support the amendment to add a spring application timing for direct seeding systems for lentils to control and suppress labelled weeds to the label of Edge MicroActiv Herbicide.

## References

<b>PMRA Document Number</b>	<b>Reference</b>
3173006	2020, Ethalfluralin Value - Trial report, DACO: 0.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173007	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173008	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173009	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173010	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173011	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173012	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173013	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173014	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173015	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173016	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173017	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173018	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173019	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173020	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173021	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173022	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173023	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173024	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
3173025	2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).

- 3173026 2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).
- 3173027 2020, Ethalfluralin Value - Trial report, DACO: 10.1, 10.2, 10.2.3, 10.2.3.4, and 10.2.3.4(B).

**© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2022**

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.